SCHEMBL3283266

SCHEMBL3283266

CCn1ncc2c(NC3CCN(C(N)=O)CC3)c(C(=O)O)cnc21

nearest known ligand 0.66

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 17/20 0.66
ADORA1 P30542 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14034599 0.95 PDE4B (0.62) PDE4BADORA1
SCHEMBL4935529 0.95 PDE4B (0.62) PDE4BADORA1
SCHEMBL4934425 0.95 PDE4B (0.62) PDE4BADORA1
SCHEMBL13324409 0.92 PDE4B (0.66) PDE4BADORA1
SCHEMBL4335271 0.91 PDE4B (0.73) PDE4BADORA1
SCHEMBL14007513 0.90 PDE4B (0.65) PDE4B
Acetic Acid SCHEMBL5962835 0.90 PDE4B (0.72) PDE4BADORA1
SCHEMBL583313 0.89 PDE4B (0.70) PDE4BADORA1
SCHEMBL3286186 0.88 PDE4B (0.79) PDE4BADORA1
SCHEMBL583135 0.87 PDE4B (0.77) PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709497-B2 Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor GLAXO GROUP LIMITED (GB) 2010-05-04 US disclosed
US-7709497-B2 Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor GLAXO GROUP LIMITED (GB) 2010-05-04 US disclosed
US-7709497-B2 Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor GLAXO GROUP LIMITED (GB) 2010-05-04 US disclosed
US-20080275078-A1 Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-06 US disclosed
US-20080275078-A1 Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-06 US disclosed
US-20080275078-A1 Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-06 US disclosed
US-20080132536-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED 2008-06-05 US disclosed
US-20080132536-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED 2008-06-05 US disclosed
US-20080132536-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED 2008-06-05 US disclosed
US-20070280971-A1 Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor GLAXO GROUP LIMITED (GB) 2007-12-06 US disclosed
US-20070280971-A1 Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor GLAXO GROUP LIMITED (GB) 2007-12-06 US disclosed
US-20070280971-A1 Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor GLAXO GROUP LIMITED (GB) 2007-12-06 US disclosed
US-20070111995-A1 Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors GLAXO GROUP LIMITED (GB) 2007-05-17 US disclosed
US-20070111995-A1 Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors GLAXO GROUP LIMITED (GB) 2007-05-17 US disclosed
US-20070111995-A1 Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors GLAXO GROUP LIMITED (GB) 2007-05-17 US disclosed
EP-1737857-A1 PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2007-01-03 EP disclosed
WO-2005090354-A1 PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2005-09-29 WO disclosed
WO-2005090352-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR GLAXO GROUP LIMITED (GB) 2005-09-29 WO disclosed
WO-2005058892-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132536-A1 PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4C PDE4B 2/4885ADORA1 285/4885
US-20070111995-A1 Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors PDE4B, PDE3B, PDE4A PDE4B 1/4885ADORA1 303/4885
US-20080275078-A1 Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors PDE4B, PDE3B, PDE4A PDE4B 1/4885ADORA1 983/4885
US-20070280971-A1 Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor PDE4B, PDE4A, PDE3B PDE4B 1/4885ADORA1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.